Axsome Therapeutics, Inc. (AXSM)
- Previous Close
71.52 - Open
70.97 - Bid 71.53 x 100
- Ask 71.81 x 100
- Day's Range
69.70 - 72.43 - 52 Week Range
55.02 - 98.40 - Volume
272,333 - Avg. Volume
718,336 - Market Cap (intraday)
3.397B - Beta (5Y Monthly) 1.10
- PE Ratio (TTM)
-- - EPS (TTM)
-5.27 - Earnings Date May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
123.00
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
www.axsome.comRecent News: AXSM
Performance Overview: AXSM
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AXSM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AXSM
Valuation Measures
Market Cap
3.40B
Enterprise Value
3.20B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.04
Price/Book (mrq)
17.79
Enterprise Value/Revenue
11.82
Enterprise Value/EBITDA
-14.21
Financial Highlights
Profitability and Income Statement
Profit Margin
-88.41%
Return on Assets (ttm)
-24.86%
Return on Equity (ttm)
-159.21%
Revenue (ttm)
270.6M
Net Income Avi to Common (ttm)
-239.24M
Diluted EPS (ttm)
-5.27
Balance Sheet and Cash Flow
Total Cash (mrq)
386.19M
Total Debt/Equity (mrq)
97.59%
Levered Free Cash Flow (ttm)
-78.72M